AsiaMedic Limited, listed on the SGX Catalist, has announced a 26% increase in revenue, reaching $12.2 million (S$16.6 million) in the first half of 2025. This growth is largely attributed to the strong performance of its diagnostic imaging services. As Singapore continues to establish itself as a regional healthcare hub, AsiaMedic is strategically positioned to cater to the rising demand for high-quality diagnostic and preventive healthcare services.
The company’s financial results highlight a robust performance in its core diagnostic imaging segment, which has been pivotal in driving the revenue surge. Despite the positive revenue growth, AsiaMedic reported a loss of $454,000 (S$616,562) for the period, an increase from the $77,000 (S$104,431) loss recorded in the same period last year. This was primarily due to increased expenses, including a significant rise in personnel costs and depreciation of right-of-use assets.
The financial report also noted a reduction in maintenance costs and an increase in laboratory and consultancy fees. The company’s strategic investments in expanding its service offerings and improving operational efficiencies are expected to bolster future performance.
AsiaMedic’s focus on enhancing its diagnostic capabilities aligns with Singapore’s vision of becoming a leading healthcare destination in the region. As the demand for accessible healthcare services continues to grow, AsiaMedic aims to leverage its expertise and infrastructure to meet these needs effectively. The company’s ongoing commitment to innovation and service excellence positions it well for future growth in the competitive healthcare sector.
“`
